<DOC>
	<DOCNO>NCT01175486</DOCNO>
	<brief_summary>Objectives : Thiazolidinediones ( TZDs ) insulin sensitizer decrease plasma glucose type 2 diabetic patient . Thiazolidinediones cause fluid retention peripheral edema diabetic patient , systematic fluid retention manifest diabetic macular edema ( DME ) . The overall goal study examine effect thiazolidinediones diabetic retinopathy nephropathy . Study design : This prospective , randomize , open-labeled , control design ass effect thiozolidinediones diabetic retinopathy nephropathy . The investigator recruit 300 type 2 diabetic patient without significant retinopathy , nephropathy cardiovascular disease . Inclusion criterion type 2 diabetes , age 30-80 year old , microabluminuria , significant retinopathy , submaximal dose sulphonylureas metformin treatment , A1C 7-9 % . Exclusion criterion insulin treatment , significant retinopathy significant nephropathy . Patients cardiovascular disease , malignancy , pregnancy , acute intercurrent illness , congestive heart failure , myocardial infarction , receive PCI CABG . All subject receive EKG CXR randomization . These subject randomize equally 3 group : acarbose , rosiglitazone pioglitazone . The investigator follow 6 month investigate short-term effect 5 year evaluate long-term outcome . The primary study end point short-term study macular thickness change measure optical coherence tomography , change level urinary albumin-to-creatinine ratio , circulate metabolic parameter adipocytokines thiozolidinediones treatment . Secondary end point fast blood glucose , A1C level , development clinically significant macular edema , serum creatinine change patient history diabetic retinopathy nephropathy baseline . The primary study end point long-term study development clinically significant macular edema time base-line visit first detection overt nephropathy . Secondary end point include development great moderate NPDR , time first event time base-line visit double serum creatinine concentration , end-stage renal disease , death .</brief_summary>
	<brief_title>Thiazolidinedione ( TZD ) Diabetic Retinopathy Nephropathy</brief_title>
	<detailed_description>The effect thiazolidinedione diabetic retinopathy nephropathy : Overall Goal Specific Aims The overall goal study examine effect thiazolidinediones diabetic retinopathy nephropathy . The specific aim : 1 . To investigate short-term effect thiazolidinediones macular thickness measure optical coherence tomography long-term effect thiazolidinediones clinically significant macular edema diabetic retinopathy document color photography fluoroscein angiography . 2 . Short-term effect thiazolidinediones change urine albumin excretion serum cardiovascular risk profile long-term effect thiazolidinediones estimate GFR change progression overt diabetic nephropathy . Objectives Thiazolidinediones ( TZDs ) insulin sensitizer decrease plasma glucose type 2 diabetic patient . Thiazolidinediones cause fluid retention peripheral edema diabetic patient , systematic fluid retention manifest diabetic macular edema ( DME ) . The overall goal study examine effect thiazolidinediones diabetic retinopathy nephropathy . Study design This prospective , randomize , open-labeled , control design ass effect thiozolidinediones diabetic retinopathy nephropathy . The investigator recruit 300 type 2 diabetic patient without significant retinopathy , nephropathy cardiovascular disease . Inclusion criterion type 2 diabetes , age 30-80 year old , microabluminuria , significant retinopathy , submaximal dose sulphonylureas metformin treatment , A1C 7-9 % . Exclusion criterion insulin treatment , significant retinopathy significant nephropathy . Patients cardiovascular disease , malignancy , pregnancy , acute intercurrent illness , congestive heart failure , myocardial infarction , receive PCI CABG . All subject receive EKG CXR randomization . These subject randomize equally 3 group : acarbose , rosiglitazone pioglitazone . The investigator follow 6 month investigate short-term effect 5 year evaluate long-term outcome . The primary study end point short-term study macular thickness change measure optical coherence tomography , change level urinary albumin-to-creatinine ratio , circulate metabolic parameter adipocytokines thiozolidinediones treatment . Secondary end point fast blood glucose , A1C level , development clinically significant macular edema , serum creatinine change patient history diabetic retinopathy nephropathy baseline . The primary study end point long-term study development clinically significant macular edema time base-line visit first detection overt nephropathy . Secondary end point include development great moderate NPDR , time first event time base-line visit double serum creatinine concentration , end-stage renal disease , death . The investigator also monitor long-term safety issue , congestive heart failure , myocardial infarction , cardiovascular event , fracture . Expected Results TZDs decrease plasma glucose type 2 diabetic patient , major side effect able cause fluid retention . This prospective study able test whether thiozolidinediones cause macular edema evaluate whether thiozolidinediones delay onset diabetic retinopathy . The investigator also able find change level urinary albumin-to-creatinine ratio , circulate metabolic parameter adipocytokines treatment TZDs Acrbose . The investigator compare time base-line visit first detection overt nephropathy , time first event composite end point time base-line visit double serum creatinine concentration , end-stage renal disease , death .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<criteria>Type 2 diabetes Age 3080 year old No significant nephropathy No significant retinopathy On submaximal dose sulphonylureas metformin treatment A1C 79 % On insulin treatment Significant retinopathy ( great moderate nonproliferative retinopathy ) Significant nephropathy ( overt proteinuria serum Cr &gt; 1.50 mg/dL ) Malignancy Pregnancy Acute intercurrent illness Congestive heart failure ( CHF , accord New York heart Association , NYHA functional class III IV ) Myocardial infarction , receive PCI CABG liver cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>thiazolidinediones</keyword>
	<keyword>diabetes</keyword>
	<keyword>retinopathy</keyword>
	<keyword>nephropathy</keyword>
</DOC>